HOME > ORGANIZATION
ORGANIZATION
- Drug Pricing Subcommittee President Bessho Calls for Correction in “Across-the-Board” Bundling
December 15, 2011
- Drug Expenditure Ratio Should Be Fixed: Professor Endo, Gakushuin University
December 15, 2011
- Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
- Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
- 129 Hospitals Stopped Providing Services in Ophthalmology Since 2008: JOA
December 13, 2011
- JMA Announces View on TPP Agreement on Website
December 12, 2011
- Osaka Bio Fund Chooses Tokyo Drug Discovery Venture as No. 3 Investment Project
December 9, 2011
- JACDS Engaged in Petition Drive to Prevent Ban on “Dispensing Point” Services
December 9, 2011
- Shortest Development, Review Periods for New Drugs in 2010: OPIR Report
December 8, 2011
- FBRI to Open Nation’s Biggest Manufacturing Facility for Investigational PET Drugs
December 7, 2011
- PSUR to Be Renamed PBRER: ICH
December 5, 2011
- JACDS Council Holds Hearings on Remote Sales of OTC Drugs
December 2, 2011
- Original Drug Makers Should Let Go of Long-Listed Drugs
December 1, 2011
- Early Exploratory Studies Should Be Conducted in Japan for Japan-originated New Drugs: FPMAJ Chairman Shoda
December 1, 2011
- HGPI Holds Forum on Global Measures for NCD Issues
November 30, 2011
- Japanese Respiratory Foundation to Promote Research, Awareness of Respiratory Diseases
November 30, 2011
- Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
- MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
- SAMURAI Biotech Association Presents Petition to Health Minister Calling for NHI Pricing System Reflecting Economic Assessment
November 25, 2011
- JPMA, FPMAJ Call on LDP Council on Budget and Tax System with Requests for Next Year
November 24, 2011
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…